The impact of interferon-β treatment on the blood-brain barrier

Drug Discovery Today

Volumn 11, Issue 15-16, 2006, Pages 755-762

  Kraus, Jörg ^a   Oschmann, Patrick ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GAMMA INTERFERON; INTERFERON BETA SERINE;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; DISEASE COURSE; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG MECHANISM; ENDOTHELIUM; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE I, RECOMBINANT; MICROSCOPY, ELECTRON, SCANNING; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS;

EID: 33745809199     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.06.008     Document Type: Review

References (60)

1. Lassmann H., et al. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7 (2001) 115-121
2. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 101 Suppl. 2 (2004) 14599-14606
3. Noseworthy J.H., et al. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
4. Steffen B.J., et al. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am. J. Pathol. 145 (1994) 189-201
5. Miller D.H., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
6. Biernacki K., et al. Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. J. Neuropathol. Exp. Neurol. 60 (2001) 1127-1136
7. Silver N.C., et al. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 51 (1998) 758-764
8. Estes M.L., et al. Stereotactic biopsy of an active multiple sclerosis lesion. Immunocytochemical analysis and neuropathologic correlation with magnetic resonance imaging. Arch. Neurol. 47 (1990) 1299-1303
9. Pozzilli C., et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 61 (1996) 251-258
10. Reiber H. Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult. Scler. 4 (1998) 99-107
11. Minagar A., et al. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 10 (2003) 299-307
12. Cossins J.A., et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. (Berl.) 94 (1997) 590-598
13. Bo L., et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36 (1994) 778-786
14. Krüger P.G. Mast cells and multiple sclerosis: a quantitative analysis. Neuropathol. Appl. Neurobiol. 27 (2001) 275-280
15. Lassmann H. Inflammation and the blood-brain barrier. Brain Pathol. 1 (1991) 88
16. Rieckmann P., et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44 (1994) 2367-2372
17. Kraus J., et al. Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity. Acta Neurol. Scand. 101 (2000) 135-139
18. Kraus J., et al. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol. Scand. 98 (1998) 102-109
19. Kraus J., et al. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J. Neuroimmunol. 122 (2002) 175-185
20. Kniesel U., and Wolburg H. Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 20 (2000) 57-76
21. Farquhar M.G., and Palade G.E. Junctional complexes in various epithelia. J. Cell Biol. 17 (1963) 375-412
22. Stewart P.A., and Hayakawa K. Early ultrastructural changes in blood-brain barrier vessels of the rat embryo. Brain Res. Dev. Brain Res. 78 (1994) 25-34
23. Dermietzel R., et al. Pattern of glucose transporter (Glut 1) expression in embryonic brains is related to maturation of blood-brain barrier tightness. Dev. Dyn. 193 (1992) 152-163
24. Qin Y., and Sato T.N. Mouse multidrug resistance 1a/3 gene is the earliest known endothelial cell differentiation marker during blood-brain barrier development. Dev. Dyn. 202 (1995) 172-180
25. Stewart P.A., and Wiley M.J. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail-chick transplantation chimeras. Dev. Biol. 84 (1981) 183-192
26. Janzer R.C., and Raff M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325 (1987) 253-257
27. Lindahl P., et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277 (1997) 242-245
28. Prat A., et al. Glial cell influence on the human blood-brain barrier. Glia 36 (2001) 145-155
29. Cecchelli R., et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36 (1999) 165-178
30. Hamm S., et al. Astrocyte mediated modulation of blood-brain barrier permeability does not correlate with a loss of tight junction proteins from the cellular contacts. Cell Tissue Res. 315 (2004) 157-166
31. Furuse M., et al. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J. Cell Biol. 147 (1999) 891-903
32. Heiskala M., et al. The roles of claudin superfamily proteins in paracellular transport. Traffic 2 (2001) 93-98
33. Nitta T., et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161 (2003) 653-660
34. Wolburg H., et al. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. (Berl.) 105 (2003) 586-592
35. Bekisz J., et al. Human interferons alpha, beta and omega. Growth Factors 22 (2004) 243-251
36. Voorthuis J.A., et al. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin. Exp. Immunol. 81 (1990) 183-188
37. Panitch H.S., et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1 (1987) 893-895
38. Jacobs L.D., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39 (1996) 285-294
39. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
40. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology 43 (1993) 655-661
41. Antonetti F., et al. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 22 (2002) 1181-1184
42. Deisenhammer F., et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 54 (2000) 2055-2060
43. Rudick R.A., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50 (1998) 1266-1272
44. The IFNB Multiple Sclerosis Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47 (1996) 889-894
45. Sorensen P.S., et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33-39
46. Laske C., et al. Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Acta Neurol. Scand. 103 (2001) 105-113
47. Gelati M., et al. Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. J. Neurol. 246 (1999) 569-573
48. Floris S., et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. J. Neuroimmunol. 127 (2002) 69-79
49. Gaillard P.J., et al. Glucocorticoid and type 1 interferon interactions at the blood-brain barrier: relevance for drug therapies for multiple sclerosis. Neuroreport 12 (2001) 2189-2193
50. Calabresi P.A., et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann. Neurol. 41 (1997) 669-674
51. Corsini E., et al. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J. Neuroimmunol. 79 (1997) 76-83
52. Ossege L.M., et al. Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II. J. Neuroimmunol. 91 (1998) 73-81
53. Kraus J., et al. Interferon-beta(1b) leads to a short-term increase of soluble but long-term stabilization of cell surface bound adhesion molecules in multiple sclerosis. J. Neurol. 251 (2004) 464-472
54. Kraus J., et al. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann. Neurol. 56 (2004) 192-205
55. Raetz C.R., and Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71 (2002) 635-700
56. Martin M.U., and Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim. Biophys. Acta 1592 (2002) 265-280
57. Prejean C., and Colamonici O.R. Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling. Semin. Cancer Biol. 10 (2000) 83-92
58. Prat A., et al. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J. Autoimmun. 24 (2005) 119-124
59. van Hinsbergh V.W., and Nieuw Amerongen G.P. Intracellular signalling involved in modulating human endothelial barrier function. J. Anat. 200 (2002) 549-560
60. Kuruganti P.A., et al. Interferon-beta counteracts inflammatory mediator-induced effects on brain endothelial cell tight junction molecules-implications for multiple sclerosis. J. Neuropathol. Exp. Neurol. 61 (2002) 710-724